C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript#Therapeutics #CCCC #Discusses #Evolving #Multiple #Myeloma #Treatments #Role #IKZF13 #Degraders #Including #Cemsidomide #Transcript